Current cancer drug targets最新文献

{"title":"Resistance by Inhibiting the STAT3/SLC25A27 Pathway and Promoting Ferroptosis in Hepatocellular Carcinoma.","authors":"Ranran Bi, Luyuan Ma, Ruolan Gu, Shilong Dong, Xinyang Li, Wenpeng Liu, Pengfei Zhang, Feng Gao, Chuan Shen, Caiyan Zhao","doi":"10.2174/0115680096426616260214221301","DOIUrl":"https://doi.org/10.2174/0115680096426616260214221301","url":null,"abstract":"<p><p>Lenvatinib is the first-line drug used in the systemic treatment of advanced hepatocellular carcinoma (HCC), although its therapeutic efficacy is limited by emerging resistance mechanisms. Our study aims to investigate the molecular pathways underlying lenvatinib resistance in HCC to inform circumvention strategies for therapeutic resistance. Our findings demonstrated that solute carrier family 25 member 27 (SLC25A27) is upregulated in lenvatinib-resistant (Lenva-R) HCC cells by RNA sequencing (RNA-seq). Similarly, SLC25A27 expression is higher in Lenva-R than lenvatinib-sensitive (Lenva-S) HCC cells and tissues via Quantitative real-time PCR (qRT-PCR), western blot, and immunohistochemistry (IHC) in vitro and vivo. Cell Counting Kit-8 (CCK-8) assay was performed to determine cell viability. Colony formation assay was performed to determine cell proliferation capacity. DCFH-DA staining was used to detect the levels of intracellular reactive oxygen species (ROS). Observation of mitochondrial morphology by using transmission electron microscopy (TEM). The corresponding assay kits were used to analyze the levels of malondialdehyde (MDA), glutathione (GSH)/ oxidized glutathione disulfide (GSSG) ratio, and mitochondrial membrane potential (MMP). Gain- and loss-of-function experiments demonstrated that SLC25A27 promotes survival, proliferation and lenvatinib resistance in vitro. Mechanistic studies showed that SLC25A27 inhibits ferroptosis pathway via activating solute carrier family 7 member A11 (SLC7A11)/glutathione peroxidase 4 (GPX4). Dual-luciferase reporter experiments confirmed signal transducer and activator of transcription 3 (STAT3) significantly enhances SLC25A27 transcription. Moreover, artesunate promotes ferroptosis by inhibiting the STAT3/SLC25A27/ SLC7A11/GPX4 axis in vivo and in vitro. Overall, our study confirmed the combination of artesunate and lenvatinib significantly enhances the anti-HCC effect of lenvatinib, which promising therapeutic strategy to circumvent resistance in HCC.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miRNAs as Theragnostic Markers for PARP Inhibitor Resistance in Breast Cancer: A Systematic Review.","authors":"Mehran Molavand, Asal Golchin, Bahman Yousefi","doi":"10.2174/0115680096450856260219065705","DOIUrl":"https://doi.org/10.2174/0115680096450856260219065705","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review aims to evaluate the potential of mi-croRNAs (miRNAs) as theragnostic biomarkers for predicting resistance to PARP inhibitors in Breast Cancer (BC), highlighting their potential for personalized treatment strategies.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we conducted a search in Scopus, EMBASE, Pub-Med, and Web of Science to identify studies on miRNAs as biomarkers for predicting PARP inhibitor response in BC. Articles were selected based on inclusion and exclusion criteria, focusing on in vitro and in vivo studies, with quality assessed using the SYRCLE tool and a customized checklist.</p><p><strong>Results: </strong>Seventeen studies were included, identifying 15 miRNAs with different expression patterns. Two main types of miRNA interactions with PARP inhibitors were observed: syn-ergistic and antagonistic effects, mediated through signaling pathway regulation and induc-tion of a BRCAness phenotype in DNA repair mechanisms.</p><p><strong>Discussion: </strong>The dual role of miRNAs in modulating PARP inhibitor response in BC is evi-dent. Several miRNAs, such as miR-451, miR-199a-3p, and miR-182, enhance PARP inhib-itor efficacy by targeting pathways like PI3K, BRCA1, and C/EBPβ. On the other hand, miR-181a and miR-214-5p contribute to resistance by upregulating STING and downregu-lating RAD51, respectively. These findings emphasize the complex role of miRNAs in ther-apy, highlighting their potential as both biomarkers and therapeutic targets in overcoming resistance.</p><p><strong>Conclusion: </strong>miRNAs are crucial in BC treatment with PARP inhibitors. Further clinical studies are needed to validate their roles and develop miRNA-based strategies to overcome PARP inhibitor resistance.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the Synergistic Effect of Chitosan Oligosaccharide and Dacarbazine (DTIC) in the Treatment of Melanoma.","authors":"Xin Zhang, Wencui Chen, Keke Zhang, Zhende Liu, Qianqian Lyu, Liming Jin, Weizhi Liu","doi":"10.2174/0115680096423297251202110111","DOIUrl":"https://doi.org/10.2174/0115680096423297251202110111","url":null,"abstract":"<p><strong>Introduction: </strong>Dacarbazine (DTIC)-based chemotherapy remains the first-line treatment for melanoma. However, its low response rate and evident side effects limit its clinical application. The combined use of chitosan oligosaccharide (COS) and other drugs has been shown to have good anti-tumor effects. Therefore, this study aimed to investigate whether COS can be combined with DTIC for the treatment of melanoma. </p><p> Methods: By constructing a tumor-bearing model, statistical analysis of tumor size, TUNEL staining, and immunohistochemical detection of CD8, F4/80, and other indicators were conducted on tumor tissue to clarify the synergistic effect and molecular mechanism of the combination therapy. </p><p> Results: The tumor-bearing model showed that the combined use of COS-2 and DTIC resulted in a tumor inhibition rate of 82.28% and enhanced the therapeutic efficacy of DTIC in mice with melanoma. COS-2 promoted the polarization of macrophages toward the M1 type and induced tumor cell apoptosis. In addition, it remarkably enhanced monocyte-mediated phagocytosis, T-lymphocyte proliferation, and immune function, thereby attenuating inflammatory responses and reducing the side effects of DTIC. </p><p> Discussion: This study highlighted the synergistic inhibitory effects of COS-2 and DTIC on the growth of melanoma both in vitro and in vivo. Notably, COS-2 not only enhanced the anti-tumor efficacy of DTIC but also alleviated its side effects. </p><p> Conclusion: The combination therapy with COS and DTIC exhibited a synergistic effect and may be a promising therapeutic strategy for melanoma.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Vision Approaches for Cervical Cancer Screening Using Pap-Smear Images: A Systematic Review.","authors":"R John Martin, Mithlesh Arya, Jayabrabu Ramakrishnan, Santhosh Joseph Menachery, Ruchi Mittal, Sujatha S, Santhi Muttipoll Dharmarajlu, Nadim Rana","doi":"10.2174/0115680096398033251128082310","DOIUrl":"https://doi.org/10.2174/0115680096398033251128082310","url":null,"abstract":"<p><p><P> Introduction: Cervical cancer continues to be a predominant cause of cancer-related mortality in women, especially in developing nations where its incidence is significantly raised. The Pap smear test is extensively utilized for early detection, and machine learning algorithms have evolved as effective strategies to improve diagnostic accuracy and efficacy. </P> <P> Methods: This systematic review, guided by PRISMA, analyzes recent machine vision-based frameworks designed for cervical cancer screening using Pap smear images. This research was classified into three primary methodological domains: segmentation, feature extraction, and classification. Besides, commonly utilized datasets were examined to evaluate their validity and relevance for cervical cancer screening applications. </P> <P> Results: This review synthesizes the methods chosen and essential elements necessary for the design of effective machine learning-based screening systems. Deep learning methods demonstrated improved accuracy when utilized with extensive annotated datasets. The absence of high-quality multi-cell datasets and inconsistencies in evaluation practices hinder comparable options among studies. </P> <P> Discussion: Results show that, despite significant progress, no single framework consistently outperform others in all contexts. Deep learning-based and hybrid models demonstrate significant potential; but, variability in datasets and evaluation methods limits their generalization and clinical implementation. Improving reproducibility and reliability necessitates addressing dataset quality, annotation standards, and benchmarking practices. </P> <P> Conclusion: This review considers the strengths and limitations of existing approaches and offers practical insights for the advancement of cervical cancer screening research. Future research must focus on the creation of standardized datasets and evaluation frameworks to improve clinical applicability and guarantee the robustness and scalability of diagnostic systems.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Product-Based Therapeutic Strategies Targeting Signaling Pathways in Prostate Cancer: A Comprehensive Review.","authors":"Riya Chaudhary, Arbab Husain, Afreen Khanam, Pratibha Pandey, Fahad Khan","doi":"10.2174/0115680096404959251120100154","DOIUrl":"https://doi.org/10.2174/0115680096404959251120100154","url":null,"abstract":"<p><p>Prostate Cancer (PCa) remains one of the leading causes of cancer-related death among men globally. While numerous traditional treatments like chemotherapy, radiation ther-apy, and surgical procedures exist, they often exhibit challenges due to drug resistance mech-anisms, off-target effects, and severe toxicity to normal tissues. Hence, finding other low-tox-icity therapeutic methods is of utmost importance. This review summarizes the ability of nat-ural product-derived therapies to target critical signaling pathways involved in PCa progres-sion, including the Androgen Receptor (AR), PI3K/AKT/mTOR, JAK/STAT, MAPK, and NF-κB pathways. Curcumin, resveratrol, genistein, and sulforaphane are natural compounds that exhibit anticancer effects by regulating these molecular pathways, thereby inhibiting tu-mor growth, inducing apoptosis, and preventing metastasis. By critically evaluating recent trends and comparing findings with current research, this review highlights the therapeutic value of these bioactive compounds. Additionally, the review discusses current knowledge gaps and proposes future research directions to optimize natural product-based interventions for PCa management.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147282870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.","authors":"Samanwita Khanra, Parikshit Roychowdhury, Nihar Ranjan Bhuyan, Gowthamarajan Kuppusamy, Kousalya Selvaraj, Jey Kumar Pachiyappan, Roshan P Rao, Imrankhan Nizam","doi":"10.2174/0115680096414252251125053406","DOIUrl":"https://doi.org/10.2174/0115680096414252251125053406","url":null,"abstract":"<p><strong>Introduction: </strong>Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is limited by low solubility, systemic toxicity, and poor bioavailability.</p><p><strong>Methods: </strong>Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were characterized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay.</p><p><strong>Results: </strong>The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h).</p><p><strong>Discussion: </strong>GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compatibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer.</p><p><strong>Conclusion: </strong>The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for colorectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of pAHSG in Omental Metastasis of Ovarian Cancer: A New Perspective on Treatment.","authors":"Haiyan Chen, Shengyuan Jiang, Yixiao Wang, Yue Wu, Dake Li, Qiaoying Zhu, Kaipeng Xie","doi":"10.2174/0115680096402184251126105331","DOIUrl":"https://doi.org/10.2174/0115680096402184251126105331","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to characterize the polypeptide expression profiles in omental metastasis of Ovarian Cancer (OC) and explore their potential applications in the treatment of OC metastasis.</p><p><strong>Methods: </strong>Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) was employed to analyze the polypeptide profiles of primary OC tissues, omental metastatic tissues, and normal omental tissues from three OC patients. Differentially expressed polypeptides were screened using bioinformatics, and three polypeptides were synthesized to investigate their functional mechanisms in OC.</p><p><strong>Results: </strong>LC-MS/MS analysis revealed 127 differentially expressed polypeptides in omental metastatic tissues compared to primary OC tissues, and 171 differentially expressed polypeptides compared to normal omental tissues. Notably, a polypeptide derived from alpha-2-macroglobulin (pAHSG) was significantly downregulated in omental metastatic tissues compared to both normal omental tissues and primary OC tissues. In vitro experiments demonstrated that pAHSG inhibited the proliferation and invasion of OC cells in a concentration-dependent manner. Flow cytometry further indicated an increase in G1 phase cells and a reduction in S phase cells following pAHSG treatment. Pull-down assays combined with mass spectrometry identified 40 proteins interacting with pAHSG, and KEGG pathway analysis revealed their involvement in aminoacyl-tRNA biosynthesis and cancer-related pathways. Collectively, these findings suggest that the downregulation of pAHSG is closely associated with omental metastasis in OC.</p><p><strong>Discussion: </strong>The polypeptide expression profiles of omental metastatic tissues in OC exhibit significant alterations. The pAHSG effectively suppresses the malignant behaviors of OC cells, providing a novel potential target for the prevention and treatment of OC metastasis.</p><p><strong>Conclusion: </strong>Compared with primary OC tissues and normal omental tissues, the polypeptide expression profiles of omental metastatic tissues exhibit significant alterations. Notably, pA-HSG, whose level is significantly changed in metastatic tissues, can effectively inhibit the malignant behaviors of OC cells, thereby providing a novel potential target for the treatment of OC metastasis.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The FHL Protein Family in Cancer: Roles, Dysregulation, and Therapeutic Implications.","authors":"Yuanzhu Zhang, Zhenghui Tian, Qiming Fan, Kexin Zhang, Xiaodong Sun, Chengxia Kan, Fang Han","doi":"10.2174/0115680096412852251126052148","DOIUrl":"https://doi.org/10.2174/0115680096412852251126052148","url":null,"abstract":"<p><p>The four-and-a-half LIM (FHL) protein family, a subgroup of the LIM-only super-family, consists of cysteine-rich cytoskeletal proteins characterized by four-and-a-half LIM domains. These proteins display tissue-specific expression and diverse cellular functions, and accumulating evidence has linked their dysregulation to tumorigenesis. FHL proteins influ-ence key biological processes, including transcriptional regulation, cytoskeletal remodeling, cell proliferation, and signaling pathway modulation, thereby contributing to cancer initiation and progression. Depending on cellular and tissue context, they may function either as tumor suppressors or as oncogenic drivers. Recent studies have highlighted their diagnostic and prog-nostic potential, as aberrant expression of FHL proteins correlates with clinical outcomes in multiple malignancies. Moreover, growing attention has been directed toward their therapeutic relevance, with efforts focusing on targeting upstream regulatory mechanisms to modulate FHL activity. This review provides an integrated overview of the structural and functional features of the FHL protein family, summarizes current understanding of their roles in cancer biology, and discusses their potential as biomarkers and therapeutic targets. By outlining the mechanisms underlying their dysregulation, this work offers new perspectives on the biologi-cal significance of FHL proteins and their implications for cancer research and clinical prac-tice.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of CD24 Expression Enhances the Anti-Melanoma Effect of Endostatin by Ameliorating Anti-Tumor Immune Responses in Melanoma-Bearing Mice.","authors":"Mengyu Lei, Zhiang Liu, Fang Lu, Wufan Zu, Mingyao Li, Ming Wang, Chaohong Deng, Meihua Fan, Yuhao Cao, Sheng Guo, Huijie Jia, Ai Cui, Tiesuo Zhao","doi":"10.2174/0115680096419727251121103534","DOIUrl":"https://doi.org/10.2174/0115680096419727251121103534","url":null,"abstract":"<p><strong>Introduction: </strong>Melanoma is a highly aggressive skin cancer that arises from transformed epidermal melanocytes and is one of the malignancies with the fastest proliferation rates globally. Angiogenesis has been identified as a critical target for melanoma therapy, and endostatin has been verified to impede endogenous angiogenesis. However, some patients' therapeutic responses remain unsatisfactory. CD24, which functions as an anti-phagocytic signal, represents a potential target for tumor immunotherapy. Thus, in this study, we investigated the anti-melanoma effects of combined CD24 inhibition and endostatin treatment.</p><p><strong>Materials and methods: </strong>The co-expressed plasmid was constructed for functional verification. A melanoma-bearing mouse model was used to observe changes in tumor size during treatment. Protein expression, apoptosis, immune cell infiltration, and macrophage subset proportions were measured using Western blot, immunofluorescence, TUNEL, and flow cytometry assays.</p><p><strong>Results: </strong>The co-expressed plasmid significantly inhibited CD24 and VEGF expression in cells. The combination therapy promoted tumor cell apoptosis and decreased angiogenesis. It also increased infiltration of M1 macrophages, T lymphocytes, and NK cells in tumor tissue and the spleen. The combined plasmid-based therapy considerably suppressed tumor growth and lengthened the survival time of mice.</p><p><strong>Discussion: </strong>The combination therapy remodeled the immunosuppressive tumor microenvironment, enhancing M1 macrophage and T lymphocyte infiltration while suppressing angiogenesis via dual inhibition of CD24 and VEGF.</p><p><strong>Conclusion: </strong>Combining CD24 inhibition with antiangiogenic therapy could offer a novel therapeutic strategy for melanoma.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Thorny Question of Early Diagnosis in Lung Cancer: Should the IP-10 Cytokine be Brought to Trial?","authors":"Yvan Sinclair Ngaha Tchawe, Freddy Elad Essogmo, Ikenna Kingsley Uchendu, Abah Moses Owoicho, Angelina V Zhilenkova, Marina Prokhorova, Natalia Nikitina, Leonid N Bagmet, Alexander S Rusanov, Elena Evgeni'evna Shchelokova, Yuliya N Pirogova, Solomon Oloche Onoja, Precious Tochukwu Nwodo, Maurelle T Sikatie, Tatiana A Demura, Marina I Sekacheva","doi":"10.2174/0115680096415381251122002921","DOIUrl":"https://doi.org/10.2174/0115680096415381251122002921","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains the leading cause of cancer mortality worldwide, underscoring the need for non-invasive early diagnostic tools. IP-10, a cytokine involved in inflammation and angiogenesis, is a promising candidate. The present study aims to assess the relevance of IP-10 in lung cancer early diagnosis.</p><p><strong>Methods: </strong>In this cross-sectional study, we measured serum IP-10 levels using Luminex assays in 52 treatment-naïve lung cancer patients without comorbidities and 14 healthy controls. Based on the non-normal distribution of data, group comparisons were performed using Wilcoxon rank-sum tests. Multivariate linear regression was used to adjust for cofounders.</p><p><strong>Results: </strong>IP-10 levels were significantly elevated in lung cancer patients compared to healthy controls (median: 189.69 pg/mL vs. 108.78 pg/mL, p = 0.001). This significance persisted in the early-stage subgroup (stages 0-IIA; median: 192.49 pg/mL vs. 108.78 pg/mL, p = 0.001), even after multivariate adjustment (p = 0.018). Levels peaked in evolved early-stage disease (median: 241.42 pg/mL) before declining in advanced stages, while remaining elevated above controls.</p><p><strong>Discussion: </strong>The rise in IP-10 levels in early-stage lung cancer patients emphasizes its potential to serve as an early diagnostic biomarker. Meanwhile, the peak-and-decline pattern during phases of disease is consistent with its postulated dual role in early antitumor immunity and later tumor promotion.</p><p><strong>Conclusion: </strong>IP-10 can potentially be used as a supplemental serum biomarker for early lung cancer diagnosis. This finding calls for additional validation in bigger, multi-center cohorts to define diagnostic thresholds and investigate their incorporation into multi-marker panels.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}